Tuberculosis and HIV co-infection: screening and treatment strategies (Q37895251)

24 August 2017

1 reference

title

Tuberculosis and HIV co-infection: screening and treatment strategies (English)

1 reference

24 August 2017

0 references

2

Soumya Swaminathan

1 reference

24 August 2017

4

Kenneth H Mayer

1 reference

24 August 2017

Kartik K Venkatesh

1

1 reference

24 August 2017

Jason R Andrews

series ordinal

3

1 reference

24 August 2017

publication date

1 June 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

71

1 reference

24 August 2017

issue

9

1 reference

24 August 2017

page(s)

1133-1152

1 reference

https://scigraph.springernature.com/pub.10.2165/11591360-000000000-00000

24 August 2017

exact match

0 references

cites work

HIV-associated tuberculosis: clinical update

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

The growing burden of tuberculosis: global trends and interactions with the HIV epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Epidemiology of HIV-associated tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Antiretroviral therapy for control of the HIV-associated tuberculosis epidemic in resource-limited settings

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Epidemiology and challenges to the elimination of global tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Tuberculosis in Europe: a problem of drug resistance or much more?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Is HIV infection a risk factor for multi-drug resistant tuberculosis? A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Multidrug-resistant and extensively drug-resistant tuberculosis: implications for the HIV epidemic and antiretroviral therapy rollout in South Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Tuberculosis control in the era of HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Towards universal access to HIV prevention, treatment, care, and support: the role of tuberculosis/HIV collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Pediatric tuberculosis: global overview and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Strategies to reduce early morbidity and mortality in adults receiving antiretroviral therapy in resource-limited settings

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Tuberculosis and HIV interaction in sub-Saharan Africa: impact on patients and programmes; implications for policies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Clinical and radiographic correlates of primary and reactivation tuberculosis: a molecular epidemiology study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Variation of chest radiographic patterns in pulmonary tuberculosis by degree of human immunodeficiency virus-related immunosuppression. The Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). The AIDS Clinical Trials Group (ACTG).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

International standards for tuberculosis care

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Clinical diagnosis of smear-negative pulmonary tuberculosis in low-income countries: the current evidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Does bleach processing increase the accuracy of sputum smear microscopy for diagnosing pulmonary tuberculosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Sputum processing methods to improve the sensitivity of smear microscopy for tuberculosis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Microscopic-observation drug-susceptibility assay for the diagnosis of TB

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Impact and cost-effectiveness of culture for diagnosis of tuberculosis in HIV-infected Brazilian adults

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

New diagnostic tests for tuberculosis: bench, bedside, and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

High rates of clinical and subclinical tuberculosis among HIV-infected ambulatory subjects in Tanzania

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Integration of tuberculosis and HIV services in sub-Saharan Africa: lessons learned

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

An algorithm for tuberculosis screening and diagnosis in people with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Symptom and chest radiographic screening for infectious tuberculosis prior to starting isoniazid preventive therapy: yield and proportion missed at screening

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Intensified tuberculosis case finding among HIV-Infected persons from a voluntary counseling and testing center in Addis Ababa, Ethiopia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Comparison of two active case-finding strategies for community-based diagnosis of symptomatic smear-positive tuberculosis and control of infectious tuberculosis in Harare, Zimbabwe (DETECTB): a cluster-randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Epidemiology of tuberculosis in a high HIV prevalence population provided with enhanced diagnosis of symptomatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Successful integration of tuberculosis and HIV treatment in rural South Africa: the Sizonq'oba study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Opportunities and challenges for HIV care in overlapping HIV and TB epidemics

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Combining PMTCT with active case finding for tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

The HIV-associated tuberculosis epidemic--when will we act?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Effect of preventive treatment for tuberculosis in adults infected with HIV: systematic review of randomised placebo controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Efficacy of secondary isoniazid preventive therapy among HIV-infected Southern Africans: time to change policy?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Tuberculosis outcomes and drug susceptibility in individuals exposed to isoniazid preventive therapy in a high HIV prevalence setting

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Tuberculosis preventive therapy in the era of HIV infection: overview and research priorities

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Prevention of tuberculosis in people living with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

The DOTS strategy for controlling the global tuberculosis epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Undiagnosed tuberculosis in a community with high HIV prevalence: implications for tuberculosis control

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

HIV infection-related tuberculosis: clinical manifestations and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Timing of initiation of antiretroviral drugs during tuberculosis therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clini

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Relapse in persons treated for drug-susceptible tuberculosis in a population with high coinfection with human immunodeficiency virus in New York City

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Treatment outcomes of patients with HIV and tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Rip Van Winkle wakes up: development of tuberculosis treatment in the 21st century

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Global tuberculosis drug development pipeline: the need and the reality.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Effects of human immunodeficiency virus infection on recurrence of tuberculosis after rifampin-based treatment: an analytical review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Evaluation of the drug interaction between rifabutin and efavirenz in patients with HIV infection and tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

From magic bullets back to the magic mountain: the rise of extensively drug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

HIV infection and multidrug-resistant tuberculosis: the perfect storm

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Exogenous reinfection as a cause of multidrug-resistant and extensively drug-resistant tuberculosis in rural South Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Early outcomes of MDR-TB treatment in a high HIV-prevalence setting in Southern Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Role of co-trimoxazole prophylaxis in reducing mortality in HIV infected adults being treated for tuberculosis: randomised clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Nutritional status of persons with HIV infection, persons with HIV infection and tuberculosis, and HIV-negative individuals from southern India

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Moderate to severe malnutrition in patients with tuberculosis is a risk factor associated with early death

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Risk factors for high early mortality in patients on antiretroviral treatment in a rural district of Malawi

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Reduced risk of tuberculosis among Brazilian patients with advanced human immunodeficiency virus infection treated with highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Antiretroviral program associated with reduction in untreated prevalent tuberculosis in a South African township

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Highly active antiretroviral treatment for the prevention of HIV transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Antiretroviral therapy for tuberculosis control in nine African countries

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Incidence of Tuberculosis among HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy in Europe and North America

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Unexpected Hepatotoxicity of Rifampin and Saquinavir/Ritonavir in Healthy Male Volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Precut tissue for descemet stripping automated endothelial keratoplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Antiretroviral therapy during tuberculosis treatment and marked reduction in death rate of HIV-infected patients, Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Timing of antiretroviral therapy initiation in tuberculosis patients with AIDS: a decision analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Treatment strategies for HIV-infected patients with tuberculosis: ongoing and planned clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Early versus delayed fixed dose combination abacavir/lamivudine/zidovudine in patients with HIV and tuberculosis in Tanzania

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Mycobacterium tuberculosis microbiologic and clinical treatment outcomes in a randomized trial of immediate versus CD4(+)-initiated antiretroviral therapy in HIV-infected adults with a high CD4(+) cell count

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Treatment of HIV-related tuberculosis in the era of effective antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Immune reconstitution and "unmasking" of tuberculosis during antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Unmasked tuberculosis and tuberculosis immune reconstitution inflammatory disease: a disease spectrum after initiation of antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Management of individuals requiring antiretroviral therapy and TB treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Effectiveness and safety of antiretrovirals with rifampicin: crucial issues for high-burden countries

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Tuberculosis and HIV co-infection: a practical therapeutic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Clinical management of tuberculosis in the context of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Treatment Options for HIV-Associated Tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Clinical experience with the combined use of lopinavir/ritonavir and rifampicin

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Isoniazid-associated hepatitis and antiretroviral drugs during tuberculosis prophylaxis in hiv-infected adults in Botswana

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Tuberculosis treatment and risk of stavudine substitution in first-line antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Safe substitution to zidovudine among HIV-infected patients initiated on stavudine-containing highly active antiretroviral therapy from a resource-limited setting

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Non-adherence to highly active antiretroviral therapy predicts progression to AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591360-000000000-00000

WHO recommends against inaccurate tuberculosis tests

21 January 2018

1 reference

12 December 2020

Tuberculosis during the first year of antiretroviral therapy in a South African cohort using an intensive pretreatment screening strategy

1 reference

12 December 2020

Will DOTS do it? A reappraisal of tuberculosis control in countries with high rates of HIV infection.

1 reference

12 December 2020

Risk factors for negative sputum acid-fast bacilli smears in pulmonary tuberculosis: results from Dakar, Senegal, a city with low HIV seroprevalence

1 reference

12 December 2020

HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality

1 reference

12 December 2020

Treatment of latent tuberculosis infection in HIV infected persons

1 reference

12 December 2020

New and improved tuberculosis diagnostics: evidence, policy, practice, and impact

1 reference

12 December 2020

Pulmonary tuberculosis in HIV-infected patients in Zaire. A controlled trial of treatment for either 6 or 12 months

1 reference

12 December 2020

Integrating nutrition support for food-insecure patients and their dependents into an HIV care and treatment program in Western Kenya

1 reference

12 December 2020

Tuberculosis in pregnancy

1 reference

12 December 2020

Immune Reconstitution Syndrome in HIV: Validating a Case Definition and Identifying Clinical Predictors in Persons Initiating Antiretroviral Therapy

1 reference

12 December 2020

Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use.

1 reference

12 December 2020

HIV-associated tuberculosis in the era of highly active antiretroviral therapy. The Adult/Adolescent Spectrum of HIV Disease Group

1 reference

12 December 2020

Polymorphisms in cytokine genes define subpopulations of HIV-1 patients who experienced immune restoration diseases

1 reference

12 December 2020

Tuberculosis risk before and after highly active antiretroviral therapy initiation: does HAART increase the short-term TB risk in a low incidence TB setting?

1 reference

12 December 2020

Safety and efficacy of nevirapine- and efavirenz-based antiretroviral treatment in adults treated for TB-HIV co-infection in Botswana

1 reference

12 December 2020

Providing HIV care for co-infected tuberculosis patients: a perspective from sub-Saharan Africa.

1 reference

12 December 2020

Tuberculosis in patients with the acquired immunodeficiency syndrome. Clinical features, response to therapy, and survival

1 reference

12 December 2020

Interventions for promoting adherence to tuberculosis management

1 reference

12 December 2020

Optimum time to initiate antiretroviral therapy in patients with HIV-associated tuberculosis: there may be more than one right answer

1 reference

12 December 2020

Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium

1 reference

12 December 2020

Integrating tuberculosis and HIV care in rural Rwanda

1 reference

12 December 2020

Antiretroviral therapy for HIV-infected tuberculosis patients saves lives but needs to be used more frequently in Thailand

1 reference

12 December 2020

Active case finding of tuberculosis: historical perspective and future prospects

1 reference

12 December 2020

Two-year follow-up of persons with HIV-1- and HIV-2-associated pulmonary tuberculosis treated with short-course chemotherapy in West Africa

1 reference

12 December 2020

Synergistic pandemics: confronting the global HIV and tuberculosis epidemics

1 reference

12 December 2020

Immune reconstitution inflammatory syndrome: risk factors and treatment implications

1 reference

12 December 2020

Relapse rates after short-course (6-month) treatment of tuberculosis in HIV-infected and uninfected persons

1 reference

12 December 2020

Normal chest radiography in pulmonary tuberculosis: implications for obtaining respiratory specimen cultures

1 reference

12 December 2020

Isoniazid tuberculosis preventive therapy in HIV-infected adults accessing antiretroviral therapy: a Botswana Experience, 2004-2006.

1 reference

12 December 2020

Approaches to tuberculosis screening and diagnosis in people with HIV in resource-limited settings

1 reference

12 December 2020

Contribution of reinfection to recurrent tuberculosis in South African gold miners

1 reference

12 December 2020

Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Côte d'Ivoire: a randomised controlled trial

1 reference

12 December 2020

Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome

1 reference

12 December 2020

Pharmacology of second-line antituberculosis drugs and potential for interactions with antiretroviral agents

1 reference

12 December 2020

10.2165/11591360-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

24 August 2017

1026820434

0 references

1 reference